The Brazil CNS Drugs market size stood at around USD 1.9 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Central nervous system diseases, is a group of neurological disorders that affects the structure or functioning of the brain or spinal cord, which collectively form the central nervous system (CNS). The CNS diseases include neurodegenerative diseases, neurodevelopmental diseases and traumatic injuries and drugs such as analgesics, anesthetics, nervous system drugs and others are used in the treatment for these diseases.
The central nervous system drug market in Brazil is driven by increasing geriatric population, health care expenditure, investment in R&D, a better understanding of the nature of neurologic diseases and improved reimbursement policies by SUS.
Whereas the restrictions by regulatory bodies on various technologies and drugs, and lack of awareness in rural area, are the factors that are hindering the growth of the market.